179 related articles for article (PubMed ID: 22632102)
21. Mathematical analysis of involvement ratio between central and peripheral COX-2 in rat pain models with two types of COX-2 inhibitors with different distribution, celecoxib and CIAA.
Okumura T; Sakakibara A; Murata Y; Kita Y
Eur J Pharmacol; 2008 Jan; 578(1):97-9. PubMed ID: 17716650
[TBL] [Abstract][Full Text] [Related]
22. Label-free global serum proteomic profiling reveals novel celecoxib-modulated proteins in familial adenomatous polyposis patients.
Fatima N; Chelius D; Luke BT; Yi M; Zhang T; Stauffer S; Stephens R; Lynch P; Miller K; Guszczynski T; Boring D; Greenwald P; Ali IU
Cancer Genomics Proteomics; 2009; 6(1):41-9. PubMed ID: 19451089
[TBL] [Abstract][Full Text] [Related]
23. Prevention of colon cancer by low doses of celecoxib, a cyclooxygenase inhibitor, administered in diet rich in omega-3 polyunsaturated fatty acids.
Reddy BS; Patlolla JM; Simi B; Wang SH; Rao CV
Cancer Res; 2005 Sep; 65(17):8022-7. PubMed ID: 16140976
[TBL] [Abstract][Full Text] [Related]
24. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations.
Guzmán HR; Tawa M; Zhang Z; Ratanabanangkoon P; Shaw P; Gardner CR; Chen H; Moreau JP; Almarsson O; Remenar JF
J Pharm Sci; 2007 Oct; 96(10):2686-702. PubMed ID: 17518357
[TBL] [Abstract][Full Text] [Related]
25. Effect of eye pigmentation on transscleral drug delivery.
Cheruvu NP; Amrite AC; Kompella UB
Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):333-41. PubMed ID: 18172110
[TBL] [Abstract][Full Text] [Related]
26. Enhanced water-soluble derivative of PC407 as a novel potential COX-2 inhibitor injectable formulation.
Liu HF; Wan N; Huan ML; Jia YY; Yuan XF; Zhou SY; Zhang BL
Bioorg Med Chem Lett; 2014 Oct; 24(20):4794-7. PubMed ID: 25248683
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of 2 celecoxib derivatives: analgesic effect and selectivity to cyclooxygenase-2/1.
Lu ZH; Xiong XY; Zhang BL; Lin GC; Shi YX; Liu ZG; Meng JR; Zhou YM; Mei QB
Acta Pharmacol Sin; 2005 Dec; 26(12):1505-11. PubMed ID: 16297351
[TBL] [Abstract][Full Text] [Related]
28. Susceptibility of glucocorticoids to colonic metabolism and pharmacologic intervention in the metabolism: implication for therapeutic activity of colon-specific glucocorticoid 21-sulfate sodium at the target site.
Kong H; Lee Y; Kim H; Hong S; Kim DD; Yoon JH; Jung Y; Kim YM
J Pharm Pharmacol; 2012 Jan; 64(1):128-38. PubMed ID: 22150680
[TBL] [Abstract][Full Text] [Related]
29. What should be considered on design of a colon-specific prodrug?
Jung Y; Kim YM
Expert Opin Drug Deliv; 2010 Feb; 7(2):245-58. PubMed ID: 20095945
[TBL] [Abstract][Full Text] [Related]
30. Studies on the development of colon-targeted delivery systems for celecoxib in the prevention of colorectal cancer.
Krishnaiah YS; Satyanarayana V; Kumar BD; Karthikeyan RS
J Drug Target; 2002 May; 10(3):247-54. PubMed ID: 12075826
[TBL] [Abstract][Full Text] [Related]
31. Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs.
Schönthal AH; Chen TC; Hofman FM; Louie SG; Petasis NA
Expert Opin Investig Drugs; 2008 Feb; 17(2):197-208. PubMed ID: 18230053
[TBL] [Abstract][Full Text] [Related]
32. Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis.
Dovizio M; Tacconelli S; Ricciotti E; Bruno A; Maier TJ; Anzellotti P; Di Francesco L; Sala P; Signoroni S; Bertario L; Dixon DA; Lawson JA; Steinhilber D; FitzGerald GA; Patrignani P
J Pharmacol Exp Ther; 2012 Apr; 341(1):242-50. PubMed ID: 22262921
[TBL] [Abstract][Full Text] [Related]
33. Analgesic effects of intrathecally administered celecoxib, a cyclooxygenase-2 inhibitor, in the tail flick test and the formalin test in rats.
Nishiyama T
Acta Anaesthesiol Scand; 2006 Feb; 50(2):228-33. PubMed ID: 16430547
[TBL] [Abstract][Full Text] [Related]
34. Celecoxib: new indication. Colorectal cancer: no preventive benefit.
Prescrire Int; 2006 Feb; 15(81):13-5. PubMed ID: 16548099
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological separation between peripheral and central functions of cyclooxygenase-2 with CIAA, a novel cyclooxygenase-2 inhibitor.
Okumura T; Murata Y; Hizue M; Matsuura T; Naganeo R; Kanai Y; Murase A; Sakakibara A; Fujita I; Nakao K
Eur J Pharmacol; 2006 Jun; 539(1-2):125-30. PubMed ID: 16690052
[TBL] [Abstract][Full Text] [Related]
36. Assessment of the potential ototoxicity of high-dose celecoxib, a selective cyclooxygenase-2 inhibitor, in rats.
Li B; Su K; Yang G; Feng Y; Xia L; Yin S
Otolaryngol Head Neck Surg; 2015 Jun; 152(6):1108-12. PubMed ID: 25779473
[TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo characteristics of celecoxib in situ formed suspensions for intra-articular administration.
Larsen SW; Frost AB; Ostergaard J; Thomsen MH; Jacobsen S; Skonberg C; Hansen SH; Jensen HE; Larsen C
J Pharm Sci; 2011 Oct; 100(10):4330-7. PubMed ID: 21598256
[TBL] [Abstract][Full Text] [Related]
38. Synthesis, characterization and in vitro studies of celecoxib-loaded poly(ortho ester) nanoparticles targeted for intraocular drug delivery.
Palamoor M; Jablonski MM
Colloids Surf B Biointerfaces; 2013 Dec; 112():474-82. PubMed ID: 24103464
[TBL] [Abstract][Full Text] [Related]
39. Application of a biphasic test for characterization of in vitro drug release of immediate release formulations of celecoxib and its relevance to in vivo absorption.
Shi Y; Gao P; Gong Y; Ping H
Mol Pharm; 2010 Oct; 7(5):1458-65. PubMed ID: 20704265
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological and pharmacokinetic evaluation of celecoxib prodrugs in rats.
Mamidi RN; Mullangi R; Kota J; Bhamidipati R; Khan AA; Katneni K; Datla S; Singh SK; Rao KY; Rao CS; Srinivas NR; Rajagopalan R
Biopharm Drug Dispos; 2002 Oct; 23(7):273-82. PubMed ID: 12355578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
